<\/p>\n\n\n\n
In recent years, precision medicine for lung cancer has evolved rapidly. The use of advanced testing technology for genomic profiling in tissue and plasma (e.g. next generation sequencing, NGS) has led to the identification of new actionable molecular drivers, including MET<\/em> exon 14 (MET<\/em>ex14) skipping mutations and other alterations. Several new targeted therapies have recently entered clinical practice based on clinically meaningful efficacy and a favorable safety profile for MET<\/em>ex14 skipping mutations. <\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n However, despite these advances, the molecular testing in clinical practice, especially for uncommon alterations, remains suboptimal and available methods are not used appropriately. Consequently, patients may not receive optimal treatment regimens. In addition, practicing physicians often don\u2019t feel confident in interpreting NGS results, treatment selection\/sequencing, and managing adverse events (AEs) to targeted therapy.<\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n Dr. Xiuning Le from MD Anderson Cancer Center will provide answers to 9 questions focusing on MET<\/em>ex14 in advanced NSCLC, to share her insights and clinical practice.<\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n This expert interview is available with subtitles in English and Chinese. <\/p>\n","protected":false},"excerpt":{"rendered":" In recent years, precision medicine for lung cancer has […]<\/p>\n","protected":false},"author":691,"featured_media":6058,"template":"","ace_education_category":[],"ace_education_tag":[],"class_list":["post-6225","ace_education","type-ace_education","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\n<\/h2>\n\n\n\n
<\/h2>\n\n\n\n
<\/h2>\n\n\n\n